Imuprin

Azathioprine, the active ingredient in Imuprin, is an immunosuppressant presented as an oral tablet for oral use. It is employed to reduce immune activity in patients undergoing organ transplantation, those with rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus.

GNH USA supplies Imuprin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Azathioprine is used to modulate immune‑mediated conditions across several disease families. - Organ transplantation: helps prevent graft rejection by suppressing the immune response. - Rheumatoid arthritis: reduces joint inflammation and disease progression. - Inflammatory bowel disease: induces and maintains remission in Crohn’s disease and ulcerative colitis. - Systemic lupus erythematosus: diminishes disease activity by limiting auto‑immune attacks.

Azathioprine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Leukopenia: reduced white blood cell count. - Rash: skin irritation or itching.

Serious or Rare Side Effects: - Bone marrow suppression: severe pancytopenia. - Hepatotoxicity: elevated liver enzymes or liver injury. - Increased infection risk: opportunistic infections.

When prescribing azathioprine, clinicians should observe several precautionary measures to ensure patient safety. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess liver function: check hepatic enzymes before and during therapy. - Avoid live vaccines: immunosuppression can lead to vaccine‑derived infection. - Counsel on infection signs: advise patients to report fever or unusual symptoms promptly. - Adjust dose in renal impairment: reduce dosage based on renal function. - Store at ambient temperature: keep tablets in original packaging, protect from moisture.

Azathioprine interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Allopurinol: may increase azathioprine toxicity; concurrent use generally avoided. - Warfarin: azathioprine can enhance anticoagulant effect, raising bleeding risk. - Live vaccines: combined immunosuppression heightens risk of infection.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may potentiate renal effects; monitor kidney function. - NSAIDs: can increase risk of bone marrow suppression; observe blood counts.